Cis-gnetin H Selective Cytotoxicity and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Limited understanding of the biological role of cis-gnetin H and trans-gnetin H, particularly their anti-tumor and anti-inflammatory mechanisms, and their potential as therapeutic agents for cancer and inflammatory conditions.
Innovation Solution
Cis-gnetin H is identified as a novel therapeutic agent for treating and preventing cancer, inhibiting tumor growth, and managing inflammation, with compositions including extracts from Paeonia suffruticosa seeds, potentially combined with other active agents, for administration via various routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cis-gnetin H is used as a therapeutic agent for cancer treatment, then anti-tumor activity is improved, but toxicity to normal cells may worsen
Solution Approach 1:
The patent applies local quality by demonstrating that cis-gnetin H exhibits selective cytotoxicity toward cancer cells while sparing normal cells. The compound targets specific molecular pathways (NF-κB, STAT3, AP-1) that are dysregulated in cancer cells but not in normal cells, creating a localized therapeutic effect at the molecular level. This selectivity is evidenced by the differential IC50 values across various cell lines, where cancer cells show significantly lower tolerance to cis-gnetin H compared to normal cells.
Solution Approach 2:
The patent inverts the conventional approach by identifying a natural compound (cis-gnetin H) that achieves the opposite effect of traditional chemotherapeutics: instead of non-selectively killing rapidly dividing cells, cis-gnetin H selectively targets cancer cells through specific molecular mechanisms while preserving normal cell function. This inversion is achieved through the compound's ability to modulate specific transcription factors and signaling pathways that are aberrantly activated in cancer but not in normal physiology.
2Reliability
If trans-gnetin H is used for cancer treatment, then anti-tumor activity is achieved, but stability and bioavailability are limited
Solution Approach 1:
The patent applies parameter changes by transitioning from trans-gnetin H to cis-gnetin H, which fundamentally alters the molecular configuration and physical-chemical properties of the compound. This geometric isomerization results in improved chemical stability, enhanced solubility, and better bioavailability while maintaining or enhancing anti-tumor activity. The cis-configuration creates a more stable molecular structure that is less prone to degradation and metabolic transformation.
Solution Approach 2:
The patent creates a superior version (cis-gnetin H) that copies the essential anti-tumor mechanism of trans-gnetin H but improves upon its structural deficiencies. The cis-isomer replicates the ability to inhibit NF-κB, STAT3, and AP-1 pathways while possessing enhanced pharmacological properties including greater stability and improved pharmacokinetic profile, making it a more viable therapeutic candidate.
3Productivity
If existing chemotherapeutic agents are used, then tumor growth is inhibited, but side effects and toxicity increase
Solution Approach 1:
The patent converts the potential harm of cytotoxicity into a benefit by utilizing cis-gnetin H's selective mechanism of action. Instead of causing widespread cell death like traditional chemotherapeutics, cis-gnetin H specifically targets cancer cells through modulation of transcription factors (NF-κB, STAT3, AP-1) that drive tumorigenesis. This transforms the harmful non-selective cytotoxicity of conventional agents into a beneficial selective anti-cancer effect that spares normal tissues.
Solution Approach 2:
The patent introduces cis-gnetin H as an intermediary compound that mediates between the host organism and the cancer pathology. Rather than directly attacking tumor cells with toxic mechanisms, cis-gnetin H acts as a molecular mediator that restores normal cellular regulation by inhibiting dysregulated transcription factors and signaling pathways, thereby achieving tumor growth inhibition through physiological modulation rather than toxic destruction.
4Reliability
If multiple stilbenes from Paeonia suffruticosa are used, then anti-inflammatory activity is achieved, but mechanism characterization is incomplete
Solution Approach 1:
The patent extracts and isolates the specific active component (cis-gnetin H) from the complex mixture of stilbenes in Paeonia suffruticosa. By separating cis-gnetin H from other compounds, the patent enables detailed mechanistic investigation of its anti-inflammatory properties. This extraction reveals that cis-gnetin H specifically inhibits NF-κB, STAT3, and AP-1 pathways, providing clear mechanistic understanding that was previously obscured by the presence of multiple active compounds in the crude extract.
Solution Approach 2:
The patent segments the anti-inflammatory effect into specific molecular targets and pathways by identifying cis-gnetin H's differential inhibition of NF-κB, STAT3, and AP-1 transcription factors. This segmentation of the mechanism into discrete, characterizable pathways provides comprehensive understanding of how the compound exerts its anti-inflammatory activity, allowing for precise mechanistic description and potential targeted therapeutic applications.
Data Source
Figure 1A~1C
Figure 2A~2B
Figure 2C
AI summary
The cis-isomer and trans-isomers of the plant-derived compound gnetin H are shown have anticancer properties, anti-inflammatory properties, and low toxicity. Therapeutic and prophylactic compositions that contain cis-gnetin H, trans-gnetin H, an derivatives thereof, as well as methods of making and using said compositions, are provided, cis-gnetin H and/or trans-gnetin H can be used in purified form or as a plant extract.